Schott Pharma Invests €100M in New Sterile Cartridge Facility in Hungary

Schott Pharma, a leading manufacturer of pharmaceutical packaging and delivery systems, has announced a significant expansion of its manufacturing capabilities in Hungary. The company is investing over €100 million ($115 million) to construct a new facility dedicated to the production of sterile ready-to-use (RTU) cartridges at its site in Lukácsháza.

Expansion Details and Strategic Importance

The new facility, which has already broken ground, will focus on producing sterile RTU cartridges used for storing biologics, including GLP-1s, insulin, and hormone therapies for diabetes, obesity, and immunological diseases. This expansion comes less than a year after Schott Pharma inaugurated a glass syringe factory at the same location, demonstrating the company's rapid growth strategy in the region.

The investment is expected to create more than 100 new jobs, nearly doubling the current workforce of 120 at the Lukácsháza site. Schott Pharma emphasizes that the new cartridge facility will be equipped with state-of-the-art manufacturing technology, featuring fully integrated and automated production processes with minimal manual intervention to maintain product sterility.

Global Manufacturing Network and Market Position

The Lukácsháza facility will become Schott Pharma's second site globally to produce sterile cartridges, complementing an existing plant in Switzerland. This expansion reinforces the company's position in the European market and its ability to meet growing demand for advanced drug delivery systems.

The move follows Schott Pharma's successful initial public offering on the Frankfurt Stock Exchange in September 2023, which CEO Andreas Reisse described as a "tremendous success." The company, originally created as a standalone business for Schott's drug packaging unit in 2022, has been actively expanding its global footprint, including recent investments in North Carolina and Serbia.

As the pharmaceutical industry continues to evolve, with a growing focus on biologics and personalized medicine, Schott Pharma's strategic investments in cutting-edge manufacturing capabilities position the company to play a crucial role in supporting drug developers and healthcare providers worldwide.